Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a tiny eye implant tame chronic uveitis Flare-Ups?

NCT ID NCT07423442

Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 100 adults with non-infectious posterior uveitis, a chronic inflammatory eye disease, who have received a fluocinolone acetonide implant. Researchers will analyze medical records over three years to see how well the implant reduces the frequency and severity of inflammatory relapses and the need for additional treatments. The goal is to better understand the implant's real-world effectiveness and safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
fluocinolone acetonide implant (a corticosteroid implant placed in the eye)
What this could lead to
If successful, this study could provide real-world evidence that the fluocinolone implant effectively reduces the number and severity of inflammatory flare-ups in people with chronic uveitis, helping to preserve vision.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other treatments or patient differences. The implant is already approved, so this study is about refining its use, not discovering a new cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients followed in ophthalmology departments of participating French university and general hospitals for non-infectious posterior uveitis or persistent posterior segment inflammation and treated with a fluocinolone acetonide intravitreal implant as part of routine clinical care.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged 18 years or older * Diagnosis of non-infectious uveitis with posterior segment involvement * Presence of uveitic macular edema or persistent posterior segment inflammation * Treatment with a fluocinolone acetonide intravitreal implant prior to January 2024 Exclusion Criteria: * Infectious uveitis * Refusal to participate or documented opposition to the study * Follow-up duration shorter than 12 months after implantation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Noninfectious posterior uveitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

posterior uveitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Noninfectious posterior uveitis Uveitic macular edema Uveitis, posterior

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Nantes - Ophthalmology Department

    Nantes, Nantes, 44000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.